Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
The main aim of this study was to determine whether gabapentin, a common adjuvant analgesic in current use against cancer-associated neuropathic pain, would affect tumour development and progression in vivo. The Dunning rat model of prostate cancer was used. UCSF scientists have found that brain cancer glioblastoma can cause cognitive decline by affecting neural connections, but the epilepsy drug gabapentin shows promise in blocking this activity, offering hope for new treatments. The main aim of this study was to determine whether gabapentin, a common adjuvant analgesic in current use against cancer-associated neuropathic pain, would affect tumour development and progression in vivo. The Dunning rat model of prostate cancer was used. The National Center for Biotechnology Information provides access to biomedical and genomic information. Epidemiologic analyses of gabapentin use and cancer risk in Kaiser Permanente Northern California were previously carried out in a collaborative study and independently evaluated in a UK database. Gabapentin is an antipain that is often used in patients with cancer pain, especially neuropathic cancer pain. 10 However, research that discusses further on the effectiveness of gabapentin for the management of patients with BTcP is still very limited. An analysis is needed to assess the effectiveness of gabapentin in the treatment of BTcP Results: Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates. Moreover, gabapentin appeared promising in reducing the need for high total doses of opioids and avoiding unplanned treatment interruptions for patients with head and neck malignancies Objective: This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain. Design: This was an open-label study. Two parallel groups of patients were recruited with either treatment-related (radiotherapy, surgery, chemotherapy) or tumor-related neuropathic pain. Gabapentinoids may offer benefits to cancer patients with pain, but careful titration and monitoring of adverse effects is necessary. More and better quality studies are required, although it may be challenging to accomplish in this patient population. Their discovery, published today in JAMA Network Open, suggests that a prophylactic, or preventative, gabapentin dose of 3600 mg daily can delay or eliminate the need for opioids to manage the pain associated with radiation-induced oral mucositis in patients with head and neck cancer. Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy. However, the studies on the treatment to date are small and several have a substantial risk of bias. The association of gabapentin with cancer was evaluated in a case-control screening study of the association of 105 drugs with 55 cancers in Kaiser Permanente Northern California (KPNC), 1994–2006. 4 The only cancer that met the screening criteria for possibly increased cancer risk with gabapentin exposure was renal (including renal pelvis We would like to show you a description here but the site won’t allow us. BACKGROUND: Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain. In recent years, GBP has been used as an adjunct or primary therapy in non-neuropathic pain, most commonly for the treatment of perioperative and cancer pain. This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Use of Gabapentin in a Cancer Hospital Open table in a new tab As systematic reviews have shown little difference in the efficacy and side effect profile of antidepressants and anticonvulsants, 2 good quality studies comparing the efficacy and side effect profile of gabapentin with these neuropathic agents are needed. show little if any evidence for carcinogenic effects of gabapentin. INTRODUCTION In 2011, we participated in a collab-orative study, headed by Michael Irizarry, MD, MPH, of GlaxoSmithKline Cor-poration, Research Triangle Park, NC, regarding the relation of gabapentin use to the risk of cancer development.1 High The main clinical uses of GBP are as an antiepileptic and as an analgesic against neuropathic pain, including cancer pain 19. Additional cancer-related uses include hot flashes, wound care and anxiolytic disorders. Gabapentin is a cyclic structural analogue of the inhibitory neurotransmitter, γ-aminobutyric acid (GABA). Given the potential benefits of gabapentin in combination with opioids for the treatment of pain syndromes related to radiation-induced mucositis, randomized clinical trials are needed to establish the role of this analgesic combination in this group of cancer patients. Conclusion: The reduced magnitude of relative risk with control for smoking and alcohol use suggests confounding by known risk factors. Biologically implausible elevated risk from just 1 prescription suggests confounding by indication. Either or both of these concerns applies to each of the 4 cancer sites associated with gabapentin use.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |